首页> 美国卫生研究院文献>other >Three Dimensional Checkerboard Synergy Analysis of Colistin Meropenem Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates
【2h】

Three Dimensional Checkerboard Synergy Analysis of Colistin Meropenem Tigecycline against Multidrug-Resistant Clinical Klebsiella pneumonia Isolates

机译:Colistin美洛培南替加环素对耐多药临床肺炎克雷伯菌分离株的三维棋盘协同分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The spread of carbapenem-non-susceptible Klebsiella pneumoniae strains bearing different resistance determinants is a rising problem worldwide. Especially infections with KPC (Klebsiella pneumoniae carbapenemase) - producers are associated with high mortality rates due to limited treatment options. Recent clinical studies of KPC-blood stream infections revealed that colistin-based combination therapy with a carbapenem and/or tigecycline was associated with significantly decreased mortality rates when compared to colistin monotherapy. However, it remains unclear if these observations can be transferred to K. pneumoniae harboring other mechanisms of carbapenem resistance. A three-dimensional synergy analysis was performed to evaluate the benefits of a triple combination with meropenem, tigecycline and colistin against 20 K. pneumoniae isolates harboring different β-lactamases. To examine the mechanism behind the clinically observed synergistic effect, efflux properties and outer membrane porin (Omp) genes (ompK35 and ompK36) were also analyzed. Synergism was found for colistin-based double combinations for strains exhibiting high minimal inhibition concentrations against all of the three antibiotics. Adding a third antibiotic did not result in further increased synergistic effect in these strains. Antagonism did not occur. These results support the idea that colistin-based double combinations might be sufficient and the most effective combination partner for colistin should be chosen according to its MIC.
机译:耐药性不同的碳青霉烯类不易感肺炎克雷伯菌的传播在世界范围内是一个日益严重的问题。特别是感染KPC(肺炎克雷伯菌肺炎克雷伯菌)的生产者,由于治疗选择有限,死亡率高。 KPC血流感染的最新临床研究表明,与大肠菌素单药疗法相比,基于大肠菌素和碳青霉烯和/或替加环素的联合疗法可显着降低死亡率。然而,尚不清楚这些观察是否可以转移到具有碳青霉烯耐药性其他机制的肺炎克雷伯菌中。进行了三维协同分析,以评估美罗培南,替加环素和大肠菌素三联体对携带不同β-内酰胺酶的20株肺炎克雷伯菌分离株的益处。为了检查临床观察到的协同作用背后的机制,还分析了外排性质和外膜孔蛋白(Omp)基因(ompK35和ompK36)。对于基于大肠菌素的双重组合,发现对三种抗生素均显示出极高的最小抑制浓度的菌株具有协同作用。在这些菌株中添加第三种抗生素不会导致进一步的协同作用。没有发生对抗。这些结果支持这样的想法,即基于大肠菌素的双重组合可能就足够了,应根据其MIC选择大肠菌素的最有效组合伴侣。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号